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Abstract Germline CDKN2A mutations occur in 40 % of
3-or-more case melanoma families while mutations of
CDK4, BAP1, and genes involved in telomere function
(ACD, TERF2IP, POT1), have also been implicated in
melanomagenesis. Mutation of the promoter of the telom-
erase reverse transcriptase (TERT) gene (c.-57 T[G
variant) has been reported in one family. We tested for the
TERT promoter variant in 675 multicase families wild-type
for the known high penetrance familial melanoma genes,
1863 UK population-based melanoma cases and 529 con-
trols. Germline lymphocyte telomere length was estimated
in carriers. The c.-57 T[G TERT promoter variant was
identified in one 7-case family with multiple primaries and
early age of onset (earliest, 15 years) but not among pop-
ulation cases or controls. One family member had multiple
primary melanomas, basal cell carcinomas and a bladder
tumour. The blood leukocyte telomere length of a carrier
was similar to wild-type cases. We provide evidence con-
firming that a rare promoter variant of TERT (c.-57 T[G)
is associated with high penetrance, early onset melanoma
and potentially other cancers, and explains\1 % of UK
melanoma multicase families. The identification of POT1
and TERT germline mutations highlights the importance of
telomere integrity in melanoma biology.
Keywords Melanoma  Familial  Genetic  TERT 
Mutation
Julia A. Newton-Bishop, David J. Adams, D. Timothy Bishop have
contributed equally to this article.
Electronic supplementary material The online version of this
article (doi:10.1007/s10689-015-9841-9) contains supplementary
material, which is available to authorized users.
& D. Timothy Bishop
D.T.Bishop@leeds.ac.uk
Mark Harland
m.harland@leeds.ac.uk
1 Section of Epidemiology and Biostatistics, Leeds Institute of
Cancer and Pathology, University of Leeds, Leeds LS9 7TF,
UK
2 Experimental Cancer Genetics, The Wellcome Trust Sanger
Institute, Hinxton, Cambridge CB10 1SA, UK
3 Department of Dermatology, Leiden University Medical
Center, Leiden, The Netherlands
4 Strangeways Research Laboratory, Departments of Public
Health and Primary Care, Centre for Cancer Genetic
Epidemiology, University of Cambridge, 2, Worts Causeway,
Cambridge CB1 8RN, UK
5 Strangeways Research Laboratory, Departments of
Oncology, Centre for Cancer Genetic Epidemiology,
University of Cambridge, 2, Worts Causeway,
Cambridge CB1 8RN, UK
6 Oncogenomics Laboratory, QIMR Berghofer Medical
Research Institute, Herston, Brisbane, QLD, Australia
7 Department of Clinical Genetics, University Hospital of
Copenhagen, Copenhagen, Denmark
8 Laboratory of Translational Genomics, Division of Cancer
Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD, USA
123
Familial Cancer (2016) 15:139–144
DOI 10.1007/s10689-015-9841-9
Background
Cutaneous melanoma occurs predominantly in the geneti-
cally predisposed, i.e. white-skinned individuals with skin
that burns easily with UV exposure, and who are prone to
develop melanocytic naevi [2, 3]. Genome-wide associa-
tion studies confirm that the strongest melanoma-associ-
ated single nucleotide polymorphisms (SNPs) align with
these melanoma-associated risk phenotypes [4].
Clustering of melanoma in families however points to
rare high-penetrance dominantly inherited mutations. The
most frequently mutated high-penetrance melanoma sus-
ceptibility gene is CDKN2A (cyclin-dependent kinase
inhibitor 2A), which encodes tumour suppressors p16 and
p14ARF. Worldwide, CDKN2A mutations explain predis-
position in approximately 40 % of families with three or
more cases of melanoma, ranging from 20 % in Australia
to 57 % in Europe [5]. The proportion of families with
identifiable CDKN2A mutations varies geographically,
being lower in countries with high ambient solar ultraviolet
radiation populated by fair-skinned people [5]. CDKN2A
mutation carriers tend to have multiple primary melano-
mas, early onset melanoma and an increased risk of
developing pancreatic cancer [5] and have also been shown
to have an increased risk of tobacco associated cancers in
respiratory and digestive tissues [6, 7]. A very small pro-
portion (\1 %) of families worldwide have been reported
with mutations in the CDK4 (Cyclin-dependent kinase 4)
gene at a key p16-binding residue [8].
Since germline CDKN2A mutations were first identified
in families there has been considerable effort to identify
additional causal (i.e. high-penetrance) mutations in novel
genes. The Melanoma Genetics Consortium (GenoMEL,
www.genomel.org) has identified a number of genes in
which mutations appear to predispose to melanoma, how-
ever the number of families in which these novel genes are
involved is few. Rare families susceptible to uveal and
cutaneous melanoma and non-melanoma cancers such as
mesothelioma and renal cell carcinoma have also been
described with inactivation of BRCA1 associated protein 1
(BAP1) [9], a gene also frequently somatically mutated in
uveal melanomas [10]. More recently, rare germline
mutations in the protection of telomeres 1 gene (POT1)
were found in families with early onset and multiple pri-
mary melanomas [11, 12]. The reported mutations abolish
the binding of POT1 (part of the shelterin complex) to
telomeres, leading to fragile telomeres and increased
telomere length, a reported association with melanoma
predisposition [13]. Mutations have also been found in
other members of the shelterin complex (ACD and TER-
F2IP) in melanoma families [14]. Despite this progress,
however, a high proportion (around 60 %) of families
worldwide cannot be explained by predisposing mutations
in known genes.
Horn et al. [1] recently identified a germline mutation in
the promoter of TERT, -57 bp (chr5:1295161 T[G,
GRCh37/hg19) from the translation start site (hereinafter
referred to as c.-57 T[G) co-segregating with melanoma
in a 14-case family. This family was characterized by early
age of onset (average 34 years) of melanoma and evidence
of susceptibility to other cancers. Two melanoma cases
developed ovarian cancer and a third had 5 different pri-
mary cancers other than melanoma (ovary, renal cell car-
cinoma, bladder, breast and lung). Further, somatic
mutations within the TERT promoter, that (similarly to the
familial c.-57 T[G variant) create a new ETS transcrip-
tion factor binding site, occur in a high proportion of
melanomas, supporting the important role of telomeres and
TERT in melanoma [15].
The inheritance of common genetic variation that pre-
dicts telomere length is a risk factor for melanoma [16] and
the identification of telomere-related genes (POT1, TERT,
ACD and TERF2IP) as highly penetrant susceptibility
genes in melanoma families suggests that telomere regu-
lation has considerable biological relevance in melanoma.
POT1 germline carriers have longer germline telomeres
than matched controls [11] there is as yet no published
evidence with regard to telomere length for individuals
carrying TERT promoter variants.
Methods
TERT promoter analyses
Screening for mutations in melanoma families
Melanoma families were recruited in Leeds, UK (data
protection and Ethical Committee reference NIGB MR64,
MREC 99/3/45), Copenhagen, Denmark (Ethics Commit-
tee of the capitol region of Copenhagen, H-3-2011-050),
Brisbane, Australia (approved by QIMR Berghofer Human
Research Ethics Committee) and Leiden, Netherlands
(ethics approval number, P00.117).
Germline DNA from the probands of 67 UK, 16 Danish,
169 Australian, and 21 Dutch families (total of 273 fami-
lies) with 3 or more cases of melanoma without known
high penetrance mutations (CDKN2A, CDK4, BAP1,
POT1, ACD, TERF2IP) were screened. A further 402
families consisting of 2 cases of melanoma recruited in the
UK (93 families), Denmark (72 families) and Australia
(237 families) were also screened.
The TERT promoter critical region (encompassing -57
to -149 bp) was amplified and capillary-sequenced using
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the same primers as described in Horn et al. [1], to examine
the c.-57 T[G germline mutation and the two most
prevalent somatic mutations (c.-124 G[A and c.-146
G[A from the translation start site [TSS]; these mutations
were termed ‘‘228’’ and ‘‘250’’ in [1] reflecting their
absolute basepair location rather than as here to the TSS).
Screening samples from population-based cases
and controls
In order to estimate the prevalence of germline TERT pro-
moter mutations in population-ascertained melanoma cases,
we screened blood-derived DNA from 1863 cases and 529
controls recruited to the Leeds Melanoma Case–Control
study [17]. A custom Taqman assay (Thermo Fisher Sci-
entific; AHGJ4ZR) was used to screen these samples for the
c.-57T[G TERT promoter variant. We also attempted to
screen the 2 main sites somatically mutated using Taqman
assays but the assay for c.-146G[A failed manufacture
(custom assay AHHS25Z for c.-124G[A).
Haplotype/relatedness studies
The 1.06 Mb risk haplotype around the c.-57 T[G TERT
promoter mutation contains 6 rare SNP variants in the
reported family [1]. To test if the variant is recurrent or a
founder mutation, we examined the segregating haplotype
for these 6 SNPs, and we conducted relatedness analysis
based on the Illumina HumanCytoSNP-12v2_H array,
publically available SNP allele frequencies and identity-
by-descent analysis using PLINK [18].
Telomere length assays
Telomere length (TL) data was available from two
approaches: (A) from whole exome sequence data with a
method described by Ding et al. [19] and (B) using a
modified q-PCR approach. For (A) germline DNA samples
from melanoma cases with a family history were subject to
targeted pulldown prior to next generation sequencing. The
algorithm estimates telomere length by counting the off-
target telomeric repeat units and normalizing by the total
number of reads with GC composition comparable to that
of the telomere region (*50 %). TL was estimated for all
41 familial melanoma cases for whom whole exome
sequencing was conducted at the Wellcome Trust Sanger
Institute; this set included samples shown to have POT1
germline mutations and previously reported showing that
persons with germline POT1 mutations associated with
dominantly inherited susceptibility to melanoma had
increased telomere length with these assays compared to
cases without POT1 mutations [11]. For (B), relative mean
TL was also estimated by a SYBR Green real-time PCR
using a version of the published q-PCR protocols modified
as described previously comparing population-based cases
with these families [20].
Results
c.257 T>G TERT promoter variant
The c.-57 T[G TERT promoter variant was identified in
the proband of a single 7-case UK family and subsequently
in a sibling (Fig. 1). The family was unusual within the UK
in that the youngest case (not tested) was 15 years old at
diagnosis, and one case had developed 7 basal cell carci-
nomas (an exceptionally large number for the UK) in
addition to melanomas and early onset borderline bladder
cancer. No case or control within the Leeds Melanoma
case–control study carried the c.-57 T[G variant.
Other promoter variants
The quality of the sequencing did not allow detailed exami-
nation of the whole of the region but we could assess the
positions-57,-124 and-146 from the TSS confidently. No
other variants were identified at these positions. Furthermore
in the case control study there was no variation shown at
position-124, a site commonly mutated somatically.
Relatedness to family reported by Horn et al
Capillary sequencing of the UK family members showed
that the variant-bearing haplotype did not contain any of
Fig. 1 Pedigree of UK family with 7 cases of melanoma in which the
c.-57 T[G TERT promoter variant was reported in 2 affected cases.
Both tested samples carried the variant allele. MM shows diagnosis of
first malignant melanoma. \n ([n) indicates first diagnosis before
(after) age n years. BCC indicates basal cell carcinoma. ? symbol
indicates germline sample carried c.-57 T[G variant. Other samples
were not available for testing
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the 6 rare variants seen in the reported family [1]. How-
ever, the two haplotypes do share the minor allele for
rs2853669 (estimated allele frequency = 0.3), which lies
in the promoter 188 bp upstream of the c.-57 T[G vari-
ant. To assess the significance, we examined the related-
ness of the families. There was strong evidence against
close relatedness of the UK family (at least 7th degree, data
not shown) with the previously reported family, suggesting
these are independently occurring mutations.
Telomere length
Telomere lengths were estimated by a bioinformatic anal-
ysis [19] and also by q-PCR. Because telomere length is
known to be dependent on methods of DNA extraction and
storage [20], this analysis was restricted to the UK families,
which were processed and stored in the same laboratory as
the identified family. Within the datasets there was evi-
dence of a reduction in telomere length with age and dif-
ferences by gender; however, because of sample sizes only
the qPCR analysis data by age showed a significant age
effect (data not shown). The bioinformatic analysis
examined whole exome data from the UK multi-case
melanoma families. The telomere length of the TERT
promoter variant carriers was within the range shown for
non-mutation carriers (Fig. 2 and Supplementary Fig. 1)
(p = 0.70 for difference in median adjusted telomere
length compared to telomeres from persons without a
known germline mutation). The POT1 mutation carriers
showed the longest telomeres as previously reported
(p\ 0.005 compared to persons without germline muta-
tions) [11]. These data were previously published [11] but
the figure is updated to indicate that two of the samples
have subsequently been shown to have the TERT promoter
mutation. In the q-PCR analysis, the telomere length of the
two c.-57 T[G TERT variant carriers (T1 and T2 in
Fig. 1) was compared to that of 250 cases without a
germline mutation but the assay repeatedly failed quality
control for one of the samples (T2). T1 had an age-adjusted
telomere length which was at the 10 % percentile of
telomere length among those without a germline mutation
(i.e. had shorter telomeres than the majority of other cases)
while once again POT1 mutation carriers had the longest
telomere length (p\ 0.001 compared to non carriers, data
not shown).
Discussion
In this report, we describe the contribution of inherited
TERT promoter mutations to melanoma susceptibility by
screening samples from 675 melanoma families consisting
of 273 with 3 or more cases and 402 with 2 cases of
melanoma. We identified the previously reported c.-57
T[G TERT promoter variant in a single 7-case family from
the UK, providing further support for this germline muta-
tion being a very rare high penetrance melanoma suscep-
tibility allele. This germline TERT promoter variant was
identified previously by Horn et al. making this only the
second family that has been identified carrying this variant
worldwide. From the size of our study and the lack of other
families with this mutation in the initial study, it is clear
that this inherited mutation is extremely rare in melanoma
families. A strength of this report is that we have screened
a substantial number of melanoma families from Australia,
Denmark, the Netherlands and the UK.
While a detailed assessment of the contribution of this
variant to melanoma risk is not feasible, we can put these
findings in some context. The UK family with the promoter
variant was identified came from a series of 139 three-or-
more case melanoma families, of which 56 (40 %) have a
CDKN2A mutation; 2 (1.4 %) have a CDK4 mutation, 4
(2.8 %) have shelterin mutations, and now 1 (0.7 %) has a
TERT promoter mutation.
In the two TERT mutation positive families, there are a
large number of melanoma cases and other cancers. Both
families had mutation carriers with bladder cancer. It is of
interest that analyses from The Cancer Genome Atlas
(TCGA) identified the TERT promoter to be a somatic
mutation hotspot for melanoma and bladder cancer as well
Fig. 2 Estimated telomere length of familial melanoma cases relative
to the telomere length of the case with the longest telomere.
Adjustment for age and sex makes minimal difference to these results
because of the limited age range of those recruited so these are the
raw estimates from bioinformatic analysis of whole exome rese-
quencing data [19]. Each sample reflects the germline DNA from a
melanoma case also with a family history. T1 and T2 refer to the 2
tested samples in Fig. 1 with the TERT promoter variant. This
figure is modified from Robles-Espinoza et al. [11]
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as glioblastoma, glioma, liver, medulloblastoma and lung
cancer [21]. It is speculative but TERT could predispose to
a broader range of cancers than melanoma.
Small numbers preclude a statistical analysis of the
numbers of naevi and atypical naevi in POT1 and TERT
mutation carriers but the POT1 mutation carriers have a
number of atypical naevi in the top 10 % of atypical naevi
among our cohort of melanoma cases (data not shown).
This might be related to factors above and beyond the
presence of the POT1 mutation (e.g. behaviour in the sun);
a much larger study is required to make more informed
comments about the naevus phenotype.
TERT encodes the enzyme telomerase reverse tran-
scriptase, a subunit of telomerase, which maintains
telomere ends by addition of the repeat TTAGGG. Over-
expression of telomerase is key component of the trans-
formation process in many malignant cancer cells. The c.57
T[G mutation is hypothesised to create an ETS tran-
scription factor binding site in the TERT promoter and so
enhance transcription of the TERT gene [1]. The rs2853669
polymorphism (at c.-246) detected in conjunction with
c.-57 T[G in both UK and reported samples has also been
reported to disrupt an ETS binding site and was associated
with low telomerase activity in patients with non small cell
lung cancer [22]. The loss of this ETS binding site might be
expected to moderate the effect of the ETS site created by
the mutation at c.-57, however the combination of both
rs2853669 and c.-57 T[G appears to result in a greater
increase in promoter activity than the presence of c.-57
T[G alone [1].
Recently, predicted telomere length (based upon inher-
itance of SNPs identified in genome-wide association
studies to be associated with telomere length) was reported
to be a risk factor for melanoma [16]. That predicted
telomere score has been established as a strong risk factor
for melanoma in the general population [16], and germline
POT1, TERT and other shelterin complex gene mutations
have been found in melanoma families, suggests that
telomere function is critical in melanoma susceptibility. In
this study we did not demonstrate increased telomere
length in the lymphocyte of TERT promoter mutation
carriers, in contrast to our recent study in which we did see
long telomeres in families with inherited mutations in
POT1 [11]. The implication is that the TERT promoter
mutation may disrupt the function of the telomere in ways
other than by simply increasing its length, as evidenced by
findings of common variants that affect cancer risk but not
directly via telomere length [20] Alternatively the effect on
telomere length may be tissue-specific and the effect differs
between melanocytic and lymphocytic.
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